Lidsky, Michael E. http://orcid.org/0000-0003-0500-2016
Wang, Zechen http://orcid.org/0000-0003-4149-5903
Lu, Min
Liu, Annie http://orcid.org/0000-0003-0729-4390
Hsu, S. David http://orcid.org/0000-0002-8149-7180
McCall, Shannon J.
Sheng, Zhecheng
Granek, Joshua A. http://orcid.org/0000-0003-3908-5016
Owzar, Kouros
Anderson, Karen S.
Wood, Kris C. http://orcid.org/0000-0002-5887-2253
Funding for this research was provided by:
Cholangiocarcinoma Foundation
U.S. Department of Health & Human Services | NIH | National Center for Advancing Translational Sciences (KL2 TR002554)
Duke Department of Surgery; Duke Cancer Institute; Duke School of Medicine Strong Start Award; American College of Surgeons National Surgeon Scientist Program
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30CA014236)
Article History
Received: 1 June 2022
Accepted: 11 October 2022
First Online: 23 October 2022
Competing interests
: K.C.W. is a founder, consultant, and equity holder at Tavros Therapeutics and Celldom and has performed consulting work for Guidepoint Global, Bantam Pharmaceuticals, and Apple Tree Partners. The remaining authors declare no competing financial or non-financial interests.